Maktaba

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.

Authors : Yin G; Department of Pharmacy, Yantai Hospital of Traditional Chinese Medicine, YantaiShandong, 264000, China.; Song G

Subjects: Fulvestrant*/Fulvestrant*/Fulvestrant*/adverse effects ; Data Mining* ; Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/statistics & numerical data

Source: Scientific reports [Sci Rep] 2024 May 18; Vol. 14 (1), pp. 11367. Date of Electronic Publication: 2024 May 18.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.

Authors : Qi Y; Tongde Hospital Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), No. 234, Gucui Road, Hangzhou, 310012, Zhejiang, China.; Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang, China.

Subjects: United States Food and Drug Administration* ; Pharmacovigilance* ; Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/statistics & numerical data

Source: Scientific reports [Sci Rep] 2024 May 18; Vol. 14 (1), pp. 11388. Date of Electronic Publication: 2024 May 18.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.

Authors : Zhu H; Department of Pharmacy, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223300, Jiangsu, China.; Wu M

Subjects: Pharmacovigilance* ; United States Food and Drug Administration* ; Adverse Drug Reaction Reporting Systems*

Source: Scientific reports [Sci Rep] 2024 May 17; Vol. 14 (1), pp. 11262. Date of Electronic Publication: 2024 May 17.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Patient-reported pain and physical health for acupuncture and chiropractic care delivered by Veterans Affairs versus community providers.

Authors : O'Hanlon CE; Veterans Affairs Greater Los Angeles Healthcare System, Center for the Study of Healthcare Innovation, Implementation & Policy (CSHIIP), Los Angeles, California, United States of America.; RAND Corporation, Santa Monica, California, United States of America.

Subjects: United States Department of Veterans Affairs* ; Acupuncture Therapy* ; Manipulation, Chiropractic*/Manipulation, Chiropractic*/Manipulation, Chiropractic*/statistics & numerical data

Source: PloS one [PLoS One] 2024 May 15; Vol. 19 (5), pp. e0303651. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081

Record details

Read Online Read More Add to Saved list

Academic Journal

The association between population health management tools and clinician burnout in the United States VA primary care patient-centered medical home.

Authors : Wang J; Department of Medicine, Stanford University, Stanford, USA.; Leung L

Subjects: Burnout, Professional*/Burnout, Professional*/Burnout, Professional*/epidemiology ; United States Department of Veterans Affairs*/United States Department of Veterans Affairs*/United States Department of Veterans Affairs*/organization & administration ; Primary Health Care*

Source: BMC primary care [BMC Prim Care] 2024 May 15; Vol. 25 (1), pp. 164. Date of Electronic Publication: 2024 May 15.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 9918300889006676 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.

Authors : Li Y; Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.; Wang X

Subjects: Dibenzothiepins*/Dibenzothiepins*/Dibenzothiepins*/adverse effects ; Triazines*/Triazines*/Triazines*/adverse effects ; Oseltamivir*/Oseltamivir*/Oseltamivir*/adverse effects

Source: BMC infectious diseases [BMC Infect Dis] 2024 May 09; Vol. 24 (1), pp. 446. Date of Electronic Publication: 2024 May 09.Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334

Record details

Read Online Read More Add to Saved list

Academic Journal

FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States.

Authors : Paniz-Mondolfi AE; Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.; Ramírez JD

Subjects: Neglected Diseases*/Neglected Diseases*/Neglected Diseases*/epidemiology ; United States Food and Drug Administration*/United States Food and Drug Administration*/United States Food and Drug Administration*/legislation & jurisprudence ; Communicable Diseases, Emerging*/Communicable Diseases, Emerging*/Communicable Diseases, Emerging*/epidemiology

Source: PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2024 May 09; Vol. 18 (5), pp. e0012116. Date of Electronic Publication: 2024 May 09 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488

Record details

Read Online Read More Add to Saved list

Academic Journal

Understanding pathways from implementation to sustainment: a longitudinal, mixed methods analysis of promising practices implemented in the Veterans Health Administration.

Authors : Nevedal AL; Center for Clinical Management Research (CCMR), Veterans Affairs Ann Arbor Healthcare System, 2215 Fuller Rd, Mail Stop 152, Ann Arbor, MI, 48105, USA. .; Widerquist MAO

Subjects: United States Department of Veterans Affairs*/United States Department of Veterans Affairs*/United States Department of Veterans Affairs*/organization & administration; United States ; Humans

Source: Implementation science : IS [Implement Sci] 2024 May 07; Vol. 19 (1), pp. 34. Date of Electronic Publication: 2024 May 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101258411 Publication Model: Electronic Cited Medium: Internet ISSN: 1748-5908

Record details

Read Online Read More Add to Saved list

Academic Journal

Clarification of Information in "Navigating Next-Generation Sequencing Laboratory Developed Tests: A Critical Look at Proficiency Testing, US Food and Drug Administration Regulations, and Clinical Laboratory Performance Tests".

Authors : Lockwood CM; Department of Laboratory Medicine and Pathology, University of Washington Medicine, Seattle.

Subjects: United States Food and Drug Administration* ; High-Throughput Nucleotide Sequencing* ; Laboratory Proficiency Testing*

Source: Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 May 01; Vol. 148 (5), pp. 507.Publisher: College of American Pathologists Country of Publication: United States NLM ID: 7607091

Record details

Read Online Read More Add to Saved list

Academic Journal

Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.

Authors : Gao W; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.; Liu J

Subjects: Drug Development*/Drug Development*/Drug Development*/methods ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/administration & dosage ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 May; Vol. 13 (5), pp. 691-709. Date of Electronic Publication: 2024 Mar 21.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model:

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.

Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.

Patient-reported pain and physical health for acupuncture and chiropractic care delivered by Veterans Affairs versus community providers.

The association between population health management tools and clinician burnout in the United States VA primary care patient-centered medical home.

Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.

FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States.

Understanding pathways from implementation to sustainment: a longitudinal, mixed methods analysis of promising practices implemented in the Veterans Health Administration.

Clarification of Information in "Navigating Next-Generation Sequencing Laboratory Developed Tests: A Critical Look at Proficiency Testing, US Food and Drug Administration Regulations, and Clinical Laboratory Performance Tests".

Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.